Machens Andreas, Schneyer Ulrich, Holzhausen Hans-Jürgen, Raue Friedhelm, Dralle Henning
Department of General Surgery, Internal Medicine, Division of Endocrinology, Martin-Luther-University Halle-Wittenberg, D-06097 Halle/Saale, Germany.
Surgery. 2004 Nov;136(5):1083-7. doi: 10.1016/j.surg.2004.04.034.
Individual germline mutations in the RET (REarranged during Transfection) proto-oncogene may set the time window for malignant progression from C-cell hyperplasia to familial medullary thyroid carcinoma. Owing to the close genotype-phenotype correlation, genetic information may lend to individual timing of prophylactic thyroidectomy according to RET genotype. Limited information exists on the Cys630 RET genotype. Most of the few published carriers of this genotype who developed medullary thyroid carcinomas (MTCs) were in their mid-30s.
This case series of a German RET family with the Cys630Arg genotype was assembled to study malignant progression of MTC in this rare RET genotype.
There was considerable variability of malignant progression from C-cell hyperplasia to MTC in carriers of the Cys630Arg genotype. In these persons, MTCs had developed by the age of 32 years (index patient, pT2bN0M0), and 15 years and 1 year (non-index patients; pT1apN1bM0 and pT1bpN0M0, respectively). The Cys630Arg genotype always segregated with the familial medullary thyroid carcinoma phenotype.
The Cys630 RET genotype may have a more vigorous transforming activity than currently thought and can cause MTC in RET gene carriers within the first year of life. Starting in early infancy, identified RET gene carriers should be scrutinized until stimulated serum calcitonin levels become positive or, when these remain normal, should undergo prophylactic thyroidectomy before they reach 5 years of age.
RET(转染期间重排)原癌基因中的个体种系突变可能设定从C细胞增生到家族性甲状腺髓样癌恶性进展的时间窗。由于紧密的基因型-表型相关性,遗传信息可能有助于根据RET基因型确定预防性甲状腺切除术的个体时机。关于Cys630 RET基因型的信息有限。少数已发表的携带该基因型并发生甲状腺髓样癌(MTC)的患者大多处于35岁左右。
收集了这个具有Cys630Arg基因型的德国RET家族的病例系列,以研究这种罕见RET基因型中MTC的恶性进展。
Cys630Arg基因型携带者从C细胞增生到MTC的恶性进展存在相当大的变异性。在这些人中,MTC在32岁时已发生(索引患者,pT2bN0M0),以及15岁和1岁时(非索引患者;分别为pT1apN1bM0和pT1bpN0M0)。Cys630Arg基因型总是与家族性甲状腺髓样癌表型相关。
Cys630 RET基因型可能具有比目前认为的更强的转化活性,并且可在生命的第一年内导致RET基因携带者发生MTC。从婴儿早期开始,已识别的RET基因携带者应接受仔细检查,直至刺激后的血清降钙素水平变为阳性,或者当这些水平保持正常时,应在5岁之前接受预防性甲状腺切除术。